The company's unique squamous program uses antigens outside the exome, aiming for strong immune responses. Data readout from Phase 1 trial depends on recruitment progress. Regulatory path for CVGBM asset unaffected by recent FDA changes.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing